Novo Nordisk continues to benefit from obesity treatments – Outlook for 2025 remains cautious
Reading Time: 3 minutes
The pharmaceutical company Novo Nordisk has released its financial figures for the past fiscal year. Lars Fruergaard Jørgensen, President and CEO, expressed satisfaction with the company's performance. He stated that more than 45 million people are now benefiting from the company's treatments. Additionally, the acquisition of three Catalent sites has been completed, and the R&D pipeline has been further developed, including obesity projects such as CagriSema and Amycretin, he commented. In the current year, the focus will remain on commercial...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
